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Abstract: Current (high throughput omics-based) data support the model that human (malignant)
germ cell tumors are not initiated by somatic mutations, but, instead through a defined locked
epigenetic status, representative of their cell of origin. This elegantly explains the role of both genetic
susceptibility as well as environmental factors in the pathogenesis, referred to as ‘genvironment’.
Moreover, it could also explain various epidemiological findings, including the rising incidence of
this type of cancer in Western societies. In addition, it allows for identification of clinically relevant
and informative biomarkers both for diagnosis and follow-up of individual patients. The current
status of these findings will be discussed, including the use of high throughput DNA methylation
profiling for determination of differentially methylated regions (DMRs) as well as chromosomal copy
number variation (CNV). Finally, the potential value of methylation-specific tumor DNA fragments
(i.e., XIST promotor) as well as embryonic microRNAs as molecular biomarkers for cancer detection
in liquid biopsies will be presented.
Keywords: biomarkers; development; epigenetics; germ cell cancer; methylation; microRNAs;
testicular cancer
1. Introduction: Germ Cell Tumors in General
1.1. Epidemiology
A number of different cell types can be found in the testis (germ cells, Sertoli cells, Leydig cells,
mesenchymal cells, mesothelial cells, among others); thus, and despite being a relatively small organ,
the testis may give rise to a large variety of neoplasms. Nonetheless, more than 95% of testicular
neoplasms are derived from germ cells arrested in their differentiation—the testicular germ cell tumors
(TGCTs) [1]—meaning that global epidemiological trends for testicular cancer mostly refer to this
group of neoplasms. Still, germ cell tumors (GCTs) are not simply a single class of neoplasms; instead,
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they represent a heterogeneous array of tumor entities, arising either in the gonads (both male and
female) or being extragonadal (developing from germ cells arrested in their migration along the
midline of the body), reflecting a complex and development-related tumor model, each subclass
showing its peculiarities and specific epidemiology. The European Cancer Registry-Based Study on
Survival and Care of Cancer Patients (EUROCARE) reports markedly distinct age-adjusted incidence
rates of GCTs in Europe for males and females (64 per 1,000,000 versus 4 per 1,000,000, respectively) [2];
besides these global differences in incidence, there are histological divergences among testicular and
ovarian neoplasms: in males most tumors are seminomas (SEs) and most non-seminomatous tumors
(NSTs) are mixed forms, while in women most tumors are NSTs and mixed forms are the exception.
TGCTs show a ‘bell-shaped’ distribution of cases with a peak around 30 years, with SEs overall
occurring 10 years later than NSTs. In the United States incidence rates were of 56 per 1,000,000 and of
only 10 per 1,000,000 in Caucasian and African-American males, respectively [3]. Only 4% of GCTs are
extragonadal, located at central nervous system, mediastinum, retroperitoneum, and pelvis, and the
majority correspond to NSTs. Incidence of GCTs overall has been increasing, especially at the expense
of TGCTs. Five-year survival is better for gonadal GCTs when compared to extragonadal GCTs [2].
Overall, testicular cancer is not a common disease, ranking as only the 21st most incident
neoplasm in men worldwide, in 2018 (with 71,105 new cases and an age standardized rate of
1.7 per 100,000). It is neither a frequent cause of cancer-related deaths, being the 27th most lethal
malignancy in men (with 9,507 estimated deaths in 2018). However, a closer look at the figures shows
it also represents the most incident and most prevalent neoplasm in males aged 15–39 years old,
at global level, with an age-standardized incidence rate of 2.7 per 100,000 in 2018 and a five-year
prevalence of 150,377 cases. Moreover, incidence is on the rise in most populations [4], with a total
of 85,635 new cases expected for 2040 (14,530 more that in 2018, representing a 20.4% increase),
and a total of 13,288 estimated deaths (3781 more than in 2018, a 39.8% increase), according to Globocan
2018 predictions [5]. Similar data is replicated by the Surveillance, Epidemiology, and End Results
Program (SEER) database; despite representing only 0.5% of all new cancer cases in the United States,
incidence rates have been rising 0.8% per year over the last 10 years and the number of new cases of
testicular cancer was 5.7 per 100,000 males per year according to 2011–2015 registries. Median age at
diagnosis is 33 years-old (25 years for NSTs, 35 years for SEs) and an intermediate 30 years for NSTs
with a SE component). The majority (68%) of patients are diagnosed with localized disease (>80% of
SEs and >60% of NSTs present with clinical stage I disease). Metastases emerge in 15% and 20% of stage
I SE and NST patients, respectively, within a period of two to three years [1]. Still, five-year survival
is outstanding (95.3%), even for patients diagnosed with distant metastases overall (73.7%) [6–8].
Importantly, variation in testicular cancer incidence rates worldwide is remarkable (29-fold variation,
being higher in Europe, Australia and the United States), and mortality-to-incidence ratio is reported
to be higher in underdeveloped regions of the globe, probably due to less access to proper healthcare
facilities, diagnostic tools, and multimodal treatments [9]. This information is summarized in
Table 1 below.
Table 1. Epidemiology of germ cell tumors: incidence, prevalence, and mortality data.
Statistics Context Source
Age adjusted incidence rates: 64/1,000,000 (males) versus
4/1,000,000 (females) Germ cell tumors Europe (EUROCARE)
Incidence rates: 0.8% rise/year
Estimated new cases: 5.7/100,000/year (all males, 2011–2015) Testicular cancer
United States of America
(SEER)
Age-standardized incidence rate: 1.7/100,000 (all males) versus
2.7/100,000 (males aged 15–39 years)
5-year prevalence: 150,377 cases (males aged 15–39 years)
Estimated new cases (85,635) and deaths (13,288) in 2040 (all males)
Testicular cancer World (Globocan)
All in all, there are a number of reasons to remain focused on TGCTs: besides the rising incidence
in part explained by Western lifestyle, about 15–20% of patients with disseminated disease experience
disease recurrence (with late relapses displaying poor prognosis); in spite of exquisite sensitivity to
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cytotoxic agents, resistance to cisplatin treatment eventually emerges in some cases, by still elusive
mechanisms; and also the diagnosis of cancer in such young patients (with long life-expectancy)
who undergo chemo and radiotherapy raises concerns over quality of life, fertility and enduring
treatment-related side effects, such as the emergence of second tumors and cardiovascular disease,
and merit proper action to prevent them [10–15].
1.2. The ‘Genvironmental’ Model
TGCTs constitute a formidable example of how genetic and environmental risk factors can
synergistically potentiate malignant transformation, in a so-called ‘genvironmental’ model [16].
1.2.1. Genetic Risk Factors
Genetic factors play an important role in TGCTs genesis; in fact, they contribute to more than
40% of TGCTs (the third highest rate among all cancer types) [17–19]. Familial risk is one of the
highest in cancer: having a brother or father diagnosed with a TGCT increases the risk eight-to-ten and
four-to-six times, respectively; the risk in monozygotic and dizygotic twins is increased 76 and 35 times,
respectively [20–22]. Also, there is an increased risk for developing cancer in the contralateral testis,
which further strengthens the influence of genetic factors and may justify performing biopsies of the
contralateral testis for identifying germ cell neoplasia in situ (GCNIS) [23,24]. Familial TGCT (FTGCT)
is indeed nowadays well recognized [25], as is the risk association with specific variants of disorders
of sex development (DSDs), also referred to as difference of sex development [26–30]. Still, more than
90% of TGCT patients end up showing no family history of TGCT. Evidence points towards the
influence of various autosomal recessive low-penetrance susceptibility genes and polymorphic gene
variants. Importantly, a model of true interplay between environmental and genetic factors is the most
likely scenario in TGCTs the ‘genvironment’. This model fits TGCTs genesis and places epigenetic
deregulation as the perfect culprit mechanism for mediating this environment-genetics interaction
and for explaining clinical findings that compose the TDS and that associate with increased risk of
TGCTs [16,31,32]. Over the years, a great effort (in the form of genome-wide association studies
(GWAS) and various metanalyses) has been put towards characterizing susceptibility alleles for
TGCTs emergence and, to date, a number of these have been determined, the ones showing the
highest odds ratio thus far being the KITLG-related [33–36]. Recently, a couple of metanalyses have
extended the number of susceptibility risk loci to 44. Importantly, these studies have put in evidence
the polygenic character of the TGCT tumor model, identifying candidate culprit single nucleotide
polymorphisms (SNPs) implicated in several distinct pathways, from the well-known KIT-KITL to
DNA damage repair (namely RAD51C and BRCA1), from sex determination/germ cell specification
(namely DMRT1, ZFPM1, and PRDM14) to apoptosis/cell cycle (including GSPT1 and CHEK2),
from telomere maintenance (including TERT and ATFIP) to centrosome organization/microtubule
assembly (TEX14, PMF1, and CENPE) [17,19,37]. Additionally, novel susceptibility markers have
been pointed out by non-GWAS studies, such as LRRC50, being a member of cilia-microtubule genes,
also known as DNAAF1 [38,39].
1.2.2. Environmental Risk Factors
Environmental risk factors can be categorized into distinct groups: the internal, less-modifiable,
developmental/medical risk factors and the external, modifiable, post-natal risk factors.
Internal Risk Factors
Overall, one can say that features comprising testicular dysgenesis syndrome (TDS) increase the
risk of TGCTs [40]; indeed, the most consistent risk factor for TGCT development is cryptorchidism,
increasing the risk in about five-fold [41], and other disorders such as hypospadias, testicular atrophy,
inguinal hernia, and impaired spermatogenesis are risk factors as well [42]. Other risk factors include
perinatal factors, such as low and high birthweight, decreased gestational age, maternal bleeding,
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and low parity. The unifying state among some of these factors is fetal exposure to estrogens and
anti-androgens, resulting in disruption of endogenous hormone signaling prenatally by exposure to
xenobiotics, leading to undervirilization of the male embryo in utero [43].
External Risk Factors
Other less established and not so well understood risk factors act postnatally; the contribution of
these factors has been assessed in several studies, achieving different and sometimes opposing conclusions.
However, although TGCTs emerge early in life, a potential role of these postnatal risk factors cannot be
ignored. These include diet (high in fat and dairy products, putting natural or synthetic hormones as
culprits), low physical exercise, environmental/occupational exposures (with increased risk in firefighters
and metal, leather, and agricultural workers) and also testicular trauma [44]. Most studies found no
association with body mass index, while most describe an association with tall stature. Late onset of puberty
has been proposed to decrease risk. Marijuana smoking is of particular interest, since it preferentially
associates with NST histology, suggesting a role in the reprogramming process [45,46]. The reason of the
other risk factors to be predominantly acting during intra-uterine development compared to marijuana use
remains to be elucidated.
1.2.3. Interplay between Environmental and Genetic Risk Factors: The ‘Genvironment’
An interplay between the aforementioned genetic and environmental factors has been demonstrated
to occur in various studies on TGCTs, with epigenetics serving as a bridge between these two aspects
of the disease. This is illustrated, for instance, by the spectrum of clinical manifestations that is TDS.
There is an association between infertility and TGCT risk, and also GCNIS lesions are found more often
in infertile men when compared to the remaining population, reflecting this link between (in)fertility,
andrological/urological abnormalities and TGCT risk, the latter being modified by a complex array of
‘genvironmental’ modifiers.
A summary of the role of these risk factors is depicted in Table 2.
Table 2. Genetic and environmental risk factors for germ cell tumors.
Factor Relative Risk OR
Genetic
Familial risk
Brother with TGCT 8–10 xs
Father with TGCT 4–6 xs
Studies in twins
Monozygotic twins 76 xs
Dizygotic twins 35 xs
Contralateral tumor 24.8–27.6
Various SNPs
KITLG-related OR >2 or <0.5
Environmental
Internal
Cryptorchidism 3.5–17.1
Infertility 1.16–6.72
Hypospadias 1.26–3.61
Atrophy 20.5
Previous inguinal hernia 1.63
Microlithiasis 3.42–13.2
Disturbed hormonal conditions in utero (maternal bleeding, first born child, low and high birthweight, short gestational age) ~1.3
Low birthweight OR 1.28
Number of siblings ≥5 OR 0.71
External
High body mass index ↑/↓/-
High stature ↑/-
Late onset of puberty ↓
Diet high in fat and dairy products ↑
Low physical exercise ↑/↓/-
Firefighters, metal/leather/agricultural workers ↑
Testicular trauma ↑
Marijuana smoking OR 1.7
Abbreviations: KITLG—KIT-ligand; OR—odds ratio; TGCT—testicular germ cell tumor.
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1.3. Classification
The first attempt to classify the various subtypes of TGCTs was accomplished by Friedman
and Moore in 1946, when they organized tumors into four groups: SEs, embryonal carcinomas
(ECs), teratomas (TEs), and teratocarcinomas [47]. Since then a multitude of classifications have been
proposed, reflecting a progressive better understanding of TGCTs tumorigenesis. The most recent 2016
World Health Organization (WHO) Classification is settled on the concept of GCNIS, and recognizes two
major types of tumors: the GCNIS-related postpubertal-types, corresponding to SEs and NSTs, and the
GCNIS-unrelated neoplasms, comprising both prepubertal-type tumors (i.e., TEs and yolk sac tumors
(YSTs) and spermatocytic tumor (ST), previously known as spermatocytic seminoma) [1,48]. With this
classification we have witnessed a transition from an essentially morphological system into one that
reflects TGCTs pathogenesis and the developmental potential of the cells from which they derive. It is,
indeed, an improvement from the former 2004 classification, which considered morphologically similar
but very distinct entities under the same group, such as the former historically erroneous designation
“spermatocytic seminoma” [49].
Novel and more profound understanding of mechanisms regulating embryogenesis and
implicated in germline allow for postulating a developmental model for GCTs in general, based on
a biologically plausible, sound and clinically relevant basis for classification. This way, Oosterhuis and
Looijenga proposed a new broad classification of GCTs, according to their developmental potential
(Table 3) [50]. The classification considers seven types of GCTs, adding type 0 (included and parasitic
twins) and type VI (arising from somatic cells which are induced to pluripotency) to the previous five
groups already acknowledged by these authors [51].
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Table 3. Proposed classification of testicular germ cell tumors, according to their developmental state (adapted from [50]).
GCT Type Age Group Sex Site Phenotype Developmental State Precursor Cell GI
0 Neonates F/M Midline Included and parasitictwins Omnipotent (2C state) Blastomere BiP
I <6 years F/M Gonads, midline TE, YST Pluripotent (primed state) Methylated PGC/gonocyte BiP to partially erased
II Postpubertal >>M Gonads, midline SE/Dysg, NST Totipotent (naïve state) Hypomethylated PGC/gonocyte Erased
III >55 years M Testis ST Spermatogonium to premeioticspermatocyte Spermatogonium/spermatocyte Partially to complete paternal
IV Postpubertal F Ovary Dermoid cyst Maternally imprinted 2C state Oogonia / oocyte Partially to complete Maternal
V Postpubertal F Placenta, uterus Hydatidiform mole Paternally imprinted 2C state Empty ovum / spermatozoa Completely paternal
VI >60 years F/M Ovary, atypical sites Resembling type I or NSTcomponents of type II
Primed state or NST lineages of naïve
state Somatic cell induced to pluripotency Pattern of originating cell
Abbreviations: BiP—biparental; Dysg—dysgerminoma; F—female; GCT—germ cell tumor; GI—genomic imprinting; M—male; NST–non-seminomatous tumors; PGC—primordial germ
cell; SE—seminoma; ST—spermatocytic tumor; TE—teratoma; YST—yolk sac tumor.
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In this review, we will be focusing especially on type II GCTs occurring in the testis, which are
the most frequent, the most histologically and clinically diverse and the most extensively studied [18].
However, some of the topics to be discussed are also of relevance for some of the other types of GCTs.
2. Pathobiology of Germ Cell Tumors and their Developmental Potential
2.1. Normal Physiology of Embryonic and Germ Cell Development
In a simple way, for full human development to take place, the omnipotent zygote needs
to undergo a program of successive restrictions of pluripotency, which is tightly regulated.
However, and for assuring maintenance of the species, totipotency of the germ cell lineage must
be essentially preserved [52].
Primordial germ cells (PGCs), the precursors of the various maturation stages of the germ cell
lineage, undergo a process of specification, proliferation and, finally, migration along the midline of
the body (explaining the topography of extragonadal GCTs), from the yolk sac, via the hindgut and
towards the genital ridge, where sex determination subsequently occurs. Once arriving at the genital
ridges they are referred to as gonocytes, which further differentiate into pre-spermatogonia or oocytes
depending on the chromosomal constitution, on the action of the major player SRY gene and on the
gonadal microenvironment, through a complex downstream signaling cascade [53,54]. During these
processes of migration and maturation, an epigenetic ‘reset’ is warranted, in the form of early global
DNA demethylation. This marks the start of the genomic imprinting (GI) cycle. GI (uncovered by
Solter and Surani in 1984 [55–58]) refers to somatic inheritance of epigenetic marks, independently
from the Mendelian laws of inheritance; in other words, it allows for some genes to be expressed
depending on the parent (maternal or paternal) of origin, thanks to parental-specific DNA methylation
and histone modifications [59]. A biparental GI is necessary for full development of the zygote, as is
a specifically methylated intact genome with X chromosome inactivation in females. After fertilization
takes place, the zygote receives a haploid set of paternally imprinted chromosomes from the father
and a haploid set of maternally imprinted chromosomes from the mother, originating a diploid zygote
with biparental GI pattern, which is replicated throughout full development of the embryo. The zygote
undergoes two waves of demethylation (active demethylation in the paternal pronucleus and passive
demethylation of the maternal genome), followed by remethylation with onset in the inner cell mass of
the developing embryo. In the germline, however, GI needs to be early erased during PGCs migration,
by means of demethylation of CpG sites, allowing for genesis of germ cells with no parental-specific
epigenetic modifications. Finally, later on, when the maturing germ cells arrive at the genital ridges
and reach mitotic (in males, spermatogenesis) or meiotic (in females, oogenesis) arrest, a restoration
of the uniparental sex-specific (maternal or paternal) GI occurs, by de novo methylation of relevant
target gene, closing the cycle [60–64] (Figure 1). Besides GI, X chromosome reactivation can be also
considered a marker of developmental stage which occurs in female germ cells before oogenesis
starts [65–67].
A full understanding of all stages of embryonic development and germ line establishment is the
cornerstone of conceiving a unifying model for the pathogenesis of GCTs, where the developmental
potential of each tumor entity is determined by the developmental state of the originating cell. This is an
appealing model, as GCTs are truly in the crossroads between cancer and developmental biology [50,68].
For instance, it is easy to conceive that type III GCTs (which refer to STs) have a developmental potential
restricted to postpubertal, premeiotic, spermatogenic cells (spermatogonium/spermatocytes) and
display a GI pattern that is partially to completely paternal, while on the other hand type IV GCTs
(which include dermoid cysts) derive from activated oocytes/ovum incapable of supporting the
development of extraembryonic tissues, presenting with a GI status that is partially to completely
maternal. Also, type V GCTs (which refer to hydatidiform moles), derive from an empty ovum that is
subsequently fertilized by one sperm, hence presenting an exclusively paternal GI pattern, having no
ability to give rise to somatic tissues.
Int. J. Mol. Sci. 2019, 20, 258 8 of 28
Figure 1. Cycle of genomic imprinting and global methylation.
2.2. Type II Germ Cell Tumors of the Testis
2.2.1. Developmental Potential
According to the proposed and above-mentioned model [50], errors in regulation of the
developmental potential of embryonic stem and early PGCs may give rise essentially to extragonadal
tumors early in life, whereas deregulation of the developmental potential already in the germline
originates a multitude of tumors preferentially located in the gonads which are primarily diagnosed
after childhood. In practice, this unifying model for GCTs enables them to be classified according
to their developmental capabilities, and categorized in groups sharing common features, such as
epidemiology, anatomical site distribution, cytogenetic abnormalities and epigenetic (de)regulation
mechanisms like GI profile.
Regarding type II GCTs, the same developmental proximity is maintained; they have the
broadest developmental potential (being in fact omnipotent) and comprise two major groups of
neoplasms, the SEs (also referred to as dysgerminoma and germinoma in the ovary and in the brain,
respectively), which derive from PGCs/gonocytes delayed in their maturation and constitute the
so-called ‘default pathway’; and the NSTs, which arise when a neoplastic PGC/gonocyte (either from
GCNIS or overt SE) undergoes a process of reprogramming, leading to the formation of a totipotent
EC cell. In turn, the latter has the capacity of originating tumor components representative of all
lineages, including the extra-embryonal YST and choriocarcinoma (CH), and the somatic-derived
TE, which includes somatic tissues from the three germ layers in varying degrees of maturation
(i.e., pluripotent). A combination of any of these components leads to the formation of mixed
tumors [69–71] (Figure 2).
In the early developmental stage of type II TGCTs, there is a continuum from a delay in
maturation of gonocytes, pre-GCNIS and GCNIS; in the latter stage the neoplastic gonocytes are
located in a territory known as spermatogonial niche, and consistently fail to switch off and hence
express OCT3/4 (a transcription factor expressed both in normal PGCs and embryonic stem cells
as well as in their neoplastic counterparts, SEs and ECs), usually in conjunction with expression
of TSPY and presence KITLG (illustrating once again that TGCTs are developmental cancers,
not due to accumulation of mutations but instead thanks to deregulation of expression of critical
differentiation-related proteins) [72,73]. GCNIS (first discovered in 1972 by Skakkebaek [74]) virtually
always progresses to overt TGCT (50% at five years and 70% at seven years [75]), passing through an
intermediate stage in the ‘default pathway’ of intratubular SE before turning into a fully invasive SE.
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An escape from the ‘default pathway’ occurs through reprogramming of a SE cell, either intratubular
or invasive, leading to emergence of an EC cell and originating NST components [76]. It remains to be
proven whether all GCNIS will become invasive tumors.
Figure 2. Pathogenesis of type II testicular germ cell tumors. Abbreviations: CH—choriocarcinoma;
EC—embryonal carcinoma; GCNIS—germ cell neoplasia in situ; SE—seminoma; TE—teratoma;
YST—yolk sac tumor.
2.2.2. Brief Pathogenetic Overview
Type II GCTs are always malignant. Most (>90%) arise in the testis (GCNIS-related
postpubertal-type tumors), the rest occurring in dysgenetic gonads and in extragonadal sites [3]. Type II
TGCTs are the most common malignancies in Caucasian males aged between 25 and 45 years-old in
Western populations; of these, slightly more than 50% are pure SEs, the second most common being
mixed tumors [4]. About 25% of these tumors are expected to be due to familial susceptibility [77].
Also, they are consistently peritriploid, being characterized by gains of the short arm of chromosome
12 (frequently in the form of isochromosome 12p, [i(12p)]) [78,79], which makes sense considering
that these tumors undergo a prolonged period of karyotype evolution since the intratubular phases
of tumor development. Polyploidization, in addition to a hypomethylated genome, contribute to
Int. J. Mol. Sci. 2019, 20, 258 10 of 28
chromosomal instability in these neoplasms, which further drives tumor progression [80]; however,
mutations and amplifications of oncogenes are rather rare in TGCTs, with KIT mutation being the most
common, especially in SEs and in bilateral cases [81–83]. In fact, recent work by Dorssers et al. [84]
has showed, by use of whole genome and targeted-sequencing, that NSTs are initiated by genome
duplication, followed by chromosome copy number alterations in cancer stem cells, with very low
accumulation of somatic mutations, even in cases resistant to therapy. Metastatic tumors show, in fact,
very little overlap with the originating primary tumor and precursor lesions, meaning that treatment
of recurrences deserve therapies targeted at their specific molecular landscape.
While differences in incidence across several regions of the globe demonstrate the relevance of
environmental factors in their genesis, contrasting incidence rates in distinct ethnic groups of the same
populations underline the contribution of genetic factors—in sum, the role of the aforementioned
‘genvironmental’ model [85].
3. Taking Advantage of the Developmental Model: Biomarkers for Clinical Implementation
3.1. Use of High-Throughput Methodologies
All seven subtypes of GCTs are derived from germ cells in distinct maturation stages and
with distinct methylation profiles. A way to both support and study this tumorigenesis model
has necessarily to pass through implementation of high-throughput, genome-wide methodologies.
The implementation of techniques such as whole genome sequencing (WGS), whole exome sequencing
(WES), targeted sequencing, RNA-sequencing (RNA-seq), miR profiling, methylation profiling/arrays
and proteomics, and their combination (with proper exclusion of contaminants such as blood
cells, stromal cells, immune cells, and compensation for other confounders), will open the door
for clarifying findings of previous studies and for uncovering novel disease biomarkers. Some of
these methodologies have already been employed in some studies and will be discussed in the
following section.
3.2. The Role of Epigenetics
Epigenetics encompasses an array of processes that change gene expression without
altering the DNA sequence, leading to a change in phenotype without changing the genotype.
It comprises covalent modifications of DNA (such as DNA methylation), histone variants,
histone| post-translational modifications, and non-coding RNAs (ncRNAs). DNA methylation,
one of the most studied mechanisms, occurs by addition of methyl groups to the fifth carbon of
cytosines, occurring preferentially at CpG sites, which are unevenly distributed in the genome—being
concentrated in the so-called CpG islands. Differential methylation of gene promoters ultimately affects
gene expression. Similarly, a number of ncRNAs are involved in the dynamic and environmentally
sensitive regulation of gene expression. These molecules are known to interact (directly or indirectly)
with the other established epigenetic mechanisms and can also directly interfere with messenger RNA
(mRNA); this way, they can be seen as an extension of the complex epigenetic network, establishing
important bridges between related modifications and truly influencing gene expression [86–88]. In this
review, we will be focusing on methylation and a subtype of ncRNAs—the microRNAs (miRs).
3.2.1. Methylation-Based Biomarkers Relating to the Developmental Model
X-chromosome inactivation (also known as lyonization [89]), a process limited to germ cells in the
male, opens the way for uncovering novel biomarkers in TGCTs, namely concerning X-inactive specific
transcript (XIST) gene, which is mapped to the X-chromosome inactivation center (XIC). In females,
XIST (a long non-coding RNA [lnc-RNA] encoded from one of the X chromosomes, which is triggered
when in cis) is responsible for inactivation (by inducing methylation of X-linked genes) of the extra
X chromosome (compensating for the increased dosage of X-linked genes when compared to male
individuals) [90,91]. The fact that TGCTs of the adult testis (SEs and NSTs) often show supernumerary
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X chromosomes suggests that XIST might also be expressed in these tumors. Indeed, both GCNIS
and overt TGCTs have been shown to express XIST (contrarily to lower expression in normal
testicular parenchyma with active spermatogenesis), which effectively rendered methylation of the
X-chromosome gene coding for androgen receptor (AR) [92]. One might say, then, that X inactivation
by XIST allows the tolerance of an excessive gain of X chromosomes in TGCTs, particularly in SEs,
which show higher expression than NSTs, meaning that this differentiation-dependent mechanism of
inactivation is indeed preserved and functional in these neoplasms [93]. In this regard, Looijenga et al.
findings [92] reflect, once again, a developmental model for TGCTs, with GCNIS and SEs showing
XIST expression still not accompanied by methylation of the inactive X chromosome (a status typical
of early germ cells), with more differentiated NSTs exhibiting both XIST expression and methylation of
the inactive X chromosome (similar to female and extraembryonic tissues), and finally ECs displaying
an intermediate pattern between the two.
TGCTs are stated to be hypomethylated when compared to other somatic-derived cancers,
which makes it difficult to uncover methylation-based biomarkers for TGCTs, especially for more
undifferentiated forms such as SEs. However, demethylated-based biomarkers might constitute a good
strategy for these tumors [94–96]. In TGCTs, XIST, which has de advantage of being expressed
specifically in male germ cells, is frequently hypomethylated at its 5′ end independently of its
expression (but more in a differentiation-dependent manner), while in somatic cells its expression is
regulated by methylation of its promoter (hypermethylation blocks XIST expression, resulting in an
active X chromosome). In this line, Kawakami et al. [97] very elegantly characterized the 5′ end of
XIST by bisulfite sequencing and identified regions I to VI, with 56 CpG sites. In their work, region IV
was found to be the most promising (consistently demethylated), and primers for the respective
methylated and unmethylated sequence were designed for conventional polymerase chain reaction
(PCR). Region IV was frequently unmethylated in TGCTs, especially in SEs and patients with advanced
disease, and no demethylated signals were detected in somatic cancers in males (serum samples
of kidney and bladder cancer patients). The authors explained the finding of some methylated
signals in TGCTs as probably due to contamination with other cells. Investing in exploring these
demethylated XIST fragments as biomarkers for TGCTs diagnosis in liquid biopsies is promising,
especially if performed in larger cohorts and if novel detection methods with higher sensitivity and
specificity are employed. These unmethylated fragments might prove very useful in the future for
follow-up of SE patients, for which no available and reliable marker exist thus far [98]. In another
study Ushida et al. [99] analyzed the methylation status of DNA repetitive elements in TGCTs,
including LINE1 and Alu repeats located at the 5′end of both E-Cadherin (CDH1) and XIST. By use of
bisulfite sequencing and combined bisulfite restriction analysis (COBRA), the authors compared
the (de)methylation profile of both TGCT cell lines, TGCT human tissues and somatic-derived
cancers (kidney cancer cell lines and testicular lymphoma tissues), showing that LINE1 was highly
hypomethylated in both SEs and NSTs; on the other hand, the two chosen Alu elements were
differentially methylated between SE and NST samples (being mainly hypomethylated in the former
and methylated in the latter). Despite somatic-derived neoplasms also exhibited partial demethylation
of these regions (perhaps reflecting the commonly accepted hypomethylation pattern of DNA repetitive
elements in cancers in general [100,101]), the degree of demethylation was not as pronounced as
in TGCT samples, hypothesizing that the genesis of these tumors and the mechanisms underlying
maintenance of demethylation of repetitive elements might differ among somatic and germ cell-derived
neoplasms. Indeed, since PGCs undergo GI erasure (including erasure of methylation in LINE1 and
Alu repeats [61]) and since SEs are composed of cells resembling PGCs/gonocytes, the (de)methylation
profile observed in SEs might be specifically related to this resemblance and not to global demethylation
observed in other cancer subtypes. Finally, the authors reported partial demethylation also in
non-cancerous testicular parenchyma adjacent to TGCTs (without evidence of GCNIS); this somewhat
unexpected finding is possibly due to epigenetic abnormalities related to defects in spermatogenesis
and those occurring in stromal cells, similar to previous findings in gastric cancer [102]. These findings
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might point towards an impact of field-cancerization, with cancer-associated stromal cells sharing
epigenetic changes with the accompanying tumor epithelial cells, and being biologically different
from normal stroma unrelated to the tumor bulk. Similarly, in testes with impaired spermatogenesis,
epigenetic aberrations (including demethylation) might have already taken place, despite no evidence
of a germ cell lesion (invasive or precursor).
The promoter methylation status of several candidate genes has been assessed in various
individual studies on TGCTs (reviewed in [103]), both in patients’ tissue and plasma cohorts and
cell lines [104–119]. Some focused on genes involved in stages of embryonic development (such as
CRIPTO [105] and OCT3/4 [116]), others on genes having a tumor-suppressor role in a variety of
neoplasms (such as RASFF1A [107,120]), others coding for DNA repair proteins (such as MGMT [109])
and others explored cancer-testis antigens (CTAs, such as PRAME [119]). Studies differ largely in
methodologies employed (and related sensitivity and specificity), patient selection and samples studied
(including distinct control samples and proportion of tumor subtypes), so they should be compared
with caution. Some of these genes were indeed included in the DMRs picked up by genome-wide
analyses [121], shedding more light on the findings of these studies.
Following the evidence that germ cells show transient erasure of GI, Killian et al. [122]
explored the GI status of TGCTs by use of genome-wide DNA methylation analysis. In their study,
the authors used only pure type II TGCT forms and neighboring testicular tissue without evidence
of GCNIS. Besides performing somatic copy number aberrations (SCNA) analysis (requiring the
gain of the short arm of chromosome 12 as an inclusion criteria), the authors introduced an adjunct
technique to methylation profiling (450K Infinium bead-array), by using lymphoid compensation (LC).
This lymphoid-compensated global methylation assessment might indeed prove very useful, as SEs,
and sometimes also NSTs, are characterized by a prominent lymphoid infiltrate which contaminates
the sample and confounds the results, possibly explaining the non-complete erasure observed in
this tumor subtype (in which almost complete erasure would be expected). The authors confirmed,
indeed, that LC resulted in shifting the peak methylation of SEs selectively close to zero, unmasking
the true and whole erasure of these tumors. This way, the authors uncovered a hypomethylation
locus which proved to be consistently present in TGCTs (both SEs and NSTs), corresponding to
hypomethylation of the DPPA3 (also known as STELLA) gene promoter. This maternal-effect gene
implicated in protecting parental imprints from erasure in the post-fertilization demethylation process,
is expressed in both TGCTs and PGCs [123], and was shown to be hypomethylated in TGCTs
(irrespective of the histology—SEs or NSTs—reflecting the pattern observed in PGCs), but always
(hyper)methylated in all tested somatic tissues. Interestingly, this promoter shows no CpG islands.
This pattern of erasure and expression is maintained despite the occurrence of de novo methylation,
meaning that DPPA3 escapes differentiation-related methylation. This points out that DPPA3 might
constitute a promising biomarker for TGCTs. Also in that study, methylation patterns of neighboring
tissue were dependent on spermatogenic proficiency. Analysis of GI revealed hypermethylation
of HM13 in NSTs and subtype-specific hypermethylation of H19 in TEs, while SEs (like GCNIS)
were globally GI-erased, implying that focal methylation observed in NST samples might occur de
novo after erasure, as suggested in other studies [124]. This might be of interest in the prediction of
development of residual mature TE in case of patients with NST treated with chemotherapy [125].
Additionally, the authors explored differentially methylated genes among the various pure tumor
entities: SEs, ECs, YSTs, CHs, and TEs.
In another study, Rijlaarsdam et al. [121] extensively profiled 91 GCTs (of subtypes I–IV,
including males and females) and four GCT cell lines (representative of type II GCTs) using the
HumanMethylation450 BeadChip (450K array, Illumina). After data processing (assuring exclusion
of confounders such as cross hybridization, SNPs, poor probe performance) a total of 437,882 valid
probes were employed, with additional annotation including small nuclear RNAs (snRNAs) and
miRs, repetitive elements and imprinted segments. Ultimately, differentially methylated genomic
regions were uncovered, allowing for clustering tumor subtypes according to their methylation
Int. J. Mol. Sci. 2019, 20, 258 13 of 28
profile. For instance, the most remarkable methylation differences were found between the cluster
composed of SEs, dysgerminomas and STs (found to be globally hypomethylated) and the one
composed of ECs, NSTs, and type I TEs (hypermethylated). Methylation profiling also allowed for
discrimination of individual tumor subtypes. Interestingly, the analysis depicted little similarity
between GCT human tissues and GCT-representative cell lines, which warrants caution when
employing these in vitro models in methylation-based analyses. Furthermore, a number of GCT
methylation-related genes were confirmed and/or uncovered with these analyses. With this study,
by studying DMRs in a genome-wide manner, the authors truly provided insight into GCTs biology
and developmental genesis, further supporting a developmental model for these tumors. In yet
another study, Noor et al. [126] explored methylation and expression profiles of GCT cell lines using
the same HumanMethylation450 BeadChip (450K array, Illumina) and the Affymetrix GeneChip
Human Genome U133 Plus 2.0 Array, disclosing that the hypermethylation status observed in YSTs is
localized to certain CpG islands in a small proportion of genes (CpG island methylator phenotype),
whereas for ECs and TEs methylation was more disperse. With this study the authors identified a wide
list of genes differentially methylated between different cell lines and an inverse correlation with
respective expression was established.
Cheung et al. [111] further studied epigenetic changes of ECs. In their study, they have
profiled six pure ECs (metastatic and non-metastatic) with methylated DNA immunoprecipitation
(MeDIP) followed by DNA-tiling hybridization (using Human Tiling Array 2.0R Chips),
identifying hypermethylated DMRs in this tumor subtype, including X- and Y-linked genes and
others related to metabolism. Follow-up on these studies might lead to identification of biomarkers for
diagnosing this aggressive tumor subtype.
More recently, an integrated analysis of TGCTs was produced by combining high-dimensional
‘omics’ assays (genomics, epigenomics, transcriptomics, and proteomics) [127]. This study included
137 TGCTs from 133 patients and confirmed the remarkably distinct global methylation status (using the
above mentioned 450K array) of different histological subtypes of TGCTs, again employing LC for
methylation (after which the methylated peak was maintained in NSTs, while the intermediate
methylation peaks disappeared in SEs). The study also depicted that ECs display methylation at
the so-called CpH sites (non-canonical cytosine sites), a finding that even correlated with the amount of
EC component, in line with the data of Killian et al. [88]. Both SEs (especially those with KIT mutations)
and the majority of NSTs disclosed lack of methylation at imprinting sites. Finally, the analyses
identified methylation of tumor suppressor genes already explored in other studies (see below), such as
BRCA1, and recognized RAD51C silencing in NSTs. As both genes are implicated in homologous
recombination (HR) DNA repair pathway, these findings seem to indicate a role of this pathway
in TGCTs.
3.2.2. MicroRNAs Relating to the Developmental Model
Control of pluripotency, early development and, subsequently, the development of GCNIS cells
implies the expression of a number of biomarkers which may ultimately be used for diagnostic
purposes, including messenger RNAs (mRNAs), protein players and also ncRNAs, such as miRs [128].
miRs are part of the small ncRNA (sncRNA) family, which means they are composed of less than
200 nt. Being the most studied, biologically relevant and versatile ncRNAs, they play important
roles in many physiological and cancer-related processes, and they do so by dynamically regulating
gene expression [129,130]. RNA-based biomarkers such as miRs display many advantages over
protein-based ones, namely higher sensitivity and specificity (PCR techniques versus antibody-based
techniques) and lower cost (as each protein requires a different antibody); and also over DNA-based
biomarkers, as they are able to reflect dynamic cellular states and some of them are able to circulate
stably in plasma and/or serum [131]. This has attracted attention towards miRs as biomarkers
suitable for testing in liquid biopsies of cancer patients, for both diagnostic, prognostic, and predictive
purposes [132]. This is particularly important in TGCTs, as commonly used serum markers
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(beta subunit of the human chorionic gonadotropin (β-HCG), alpha-fetoprotein (AFP), and lactate
dehydrogenase (LDH)) have limited diagnostic performance, especially in certain tumor subtypes
such as SE and EC [133]. In this vein, significant effort has been invested in translating miR testing to
the clinics, hence the numerous publications in the field (Figure 3).
Figure 3. Chronological view of most relevant publications regarding microRNAs in testicular germ
cell tumors (see text for details).
Voorhoeve et al. [134] were pioneers in identifying miRs that function as oncogenes (oncomiRs) in
TGCTs by use of a miR library; they uncovered miR-372 and miR-373 role in neutralizing p53 function,
by directly inhibiting the expression of the LATS2 tumor suppressor. This mechanism constitutes
an explanation for tumor progression in TGCTs, which typically show absence of p53 mutations
(i.e., they harbor wild-type p53). Gillis et al. [135] pursued a high throughput screen of 156 miRs in GCT
tissues and cell lines, confirming the relevance of the miR-371–373 cluster. Also, they demonstrated
variations in miR expression relating to degree of maturation, again establishing a parallelism between
GCTs development and embryogenesis, allowing for discrimination of tumor subtypes. Another study
also profiled 615 miRs in GCTs, again confirming the value of miR-371~373 and miR-372 clusters,
which were elevated in all histological subtypes, both in adult and pediatric patients [136]. These miRs
were also documented to be overexpressed in GCNIS tissues [137]. Vilela-Salgueiro et al. [138]
also examined TGCT tissues and showed miR-371a-3p discriminated TGCTs from normal testicular
parenchyma with high sensitivity and specificity, rendering an area under the curve (AUC) of 0.99.
Additionally, higher expression levels of this miR was apparent in SEs compared to NSTs, and also
among individual NST subtypes, with tumor samples showing a decreasing expression of miR-371a-3p
in parallel with tumor differentiation. The authors have also showed that miR-371a-3p was able to
discriminate TE tissue samples (including pure TE and TE component isolated from mixed tumors,
with diverse degrees of maturation) from normal testis, although in serum this could not be confirmed
so far, which might impair its use as a biomarker, particularly in predicting residual pure TE after
chemotherapy (see below) [138–140].
Expression of these promising miR clusters was early pursued in serum and plasma samples.
Indeed, Murray et al. [141] soon documented that the most relevant members of the miR-371~373
and miR-372 clusters were elevated at diagnosis in the serum of a four-year-old boy with a YST,
and that levels decreased after surgery and chemotherapy, opening the way for exploring these
biomarkers in this line [142,143]. Indeed, since then, numerous publications exploring the potential of
these miR clusters have been published and extended the findings of this sole case report into large
cohorts of patients representative of various tumor entities [144,145]. Dieckmann et al. [146] further
innovated by measuring miR-371-3 directly from testicular vein blood, which directly drains from
the tumor; not surprisingly, the latter samples showed higher expression levels when compared to
cubital vein-derived blood. The authors also measured the expression of this miR in tissues, but levels
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showed no correlation with the ones in serum. This was also reported by the Looijenga group [128,147].
The clinical utility of measuring serum miR-371a-3p was, hence, demonstrated [148].
Methodologies for detection of these miRs in serum evolved; Gillis et al. [147] used the
targeted serum miR (TSmiR) test in GCTs and healthy control males, and showed overexpression of
miR-371/372/373/367 in GCT patients, which decreased towards baseline after treatment, disclosing
98% sensitivity. Also, there was a trend for higher expression levels of these miRs in patients with
metastases, pointing towards an association with tumor burden. Soon, novel miRs were also uncovered
by high-throughput methods, including miR-511, -26b, -769, -23a, -106b, -365, -598, -340, and let-7a [149].
Spiekermann et al. [150] also described that miR-371-3 expression levels might be assessed without
the need for an endogenous control if experiments were performed under controlled conditions.
Other bodily fluids were soon tested for miR-371a-3p expression levels: high expression levels
were depicted in pleural effusions and seminal plasma of patients, but not in urine samples [151].
However, another study showed that miR-142 was upregulated in seminal plasma from TGCT patients,
but that miR-371-3 (along with miR-34b) were downregulated compared to controls, contrarily to
the previous study [152]. High expression levels were also depicted in hydrocele fluid surrounding
tumors [153] and also in cerebral spinal fluid (CSF) of pediatric patients with extragonadal malignant
GCTs, allowing for discrimination from intracranial non-GCTs and allowing detection of relapses
with high sensitivity and specificity [154]. To date, the miR with the best overall performance in
serum samples was shown to be miR-371a-3p (with a sensitivity of 88.7% and specificity of 93.4%);
also, expression levels correlated with relapse and dropped after treatment [155], and may additionally
be used for detecting patients with GCNIS, possibly guiding the decision to perform a testicular biopsy
in this context [156]. miR-371a-3p expression was also shown to outperform classical serum markers
in detecting disease relapse, except in TEs [140,157].
The largest series evaluated thus far identified (with ampTSmiR test) miR-371a-3p, 373-3p,
and 367-3p as highly sensitive and specific in TGCTs diagnosis (joint AUC of 0.96) [139]. More recently
the work of Leão et al. [158] provided answers to a clinically relevant scenario, which is the detection
of residual disease post-chemotherapy, as there are no validated markers for predicting viable disease
and up to 50% of cases show only fibrosis and necrosis. This way, a biomarker for predicting viable
disease is desirable, perhaps avoiding unnecessary surgery and related morbidity. In their work, it was
shown that miR-371a-3p discriminated viable disease with an AUC of 0.87. Further studies on this
subject are, however, necessary for clinical implementation to take place. Finally, Radtke et al. [159]
analyzed stage I TGCT patients and demonstrated that miR-371a-3p has a very short half-life (less than
12 h), decaying very rapidly in the following three days after orchiectomy. Also, Mego et al. [160,161]
reported the clinical utility of using miR-371a-3p plasma levels in predicting patient outcome in
a population of TGCT patients set to be submitted to first line chemotherapy (higher levels associating
with higher tumor burden and disease extent and negative levels culminating in better overall and
progression-free survival).
All in all, miRs have shown great potential as biomarkers of both type I and type II GCTs, and also
of GCNIS, and they are promising means for diagnosing and monitoring these patients. Their possible
role as therapeutic targets is still largely unexplored and might constitute a promising way of avoiding
cytotoxic treatments and its long-term side effects in such young patients [18]. A recent paper from
Salvatori et al. [162] has used a mouse model for showing that plasma levels of miRs 371/302/C19MC
were accurate in detecting undifferentiated and malignant components arising in xenografts derived
from mice injected with human pluripotent stem cell (hPSC) lines and human malignant GCT cell
lines. This study supports that these miRs might predict the emergence of malignancy in patients
undergoing transplantation of hPSCs as a means of therapy, which thus far could only be determined
by classical histological evaluation of TEs [163–165].
Besides methylation-related data, the already mentioned integrated study [127] depicted
differentially expressed miRs (miR-sequencing (miR-seq) data) among tumor subtypes: it introduced
the miR-519 cluster as being overexpressed in ECs (probably negatively regulating transcripts in
Int. J. Mol. Sci. 2019, 20, 258 16 of 28
this tumor subtype) and further confirmed miR-371a-3p value as a TGCT biomarker across subtypes
(with the possible exception of TEs). It also disclosed miR-375 overexpression in TEs and YSTs, but not
in ECs and SEs, meaning that it might complement miR-371a-3p expression assessment, especially in
serum samples.
A summary of the mentioned studies on TGCT biomarkers regarding both methylation and miRs
is depicted in Table 4.
Table 4. Summary of studies on testicular germ cell tumor biomarkers regarding methylation
and microRNAs.
Methodology Sample Type Major Findings Year Author
Methylation
Bisulfite
sequencing; PCR
Tissues (n = 31 TGCTs) and
plasma (n = 25 TGCT samples,
n = 24 non-TGCT samples)
XIST region IV frequently
unmethylated in TGCTs,
especially in SEs
2004 Kawakami et al.
Bisulfite
sequencing;
COBRA
Tissues (n = 14 TGCTs, n = 10
adjacent testicular parenchyma,
n = 3 non-TGCTs) and TGCT cell
lines
LINE1 hypomethylated in both
SEs and NSTs; XIST and CDH1
mainly hypomethylated in SEs
and methylated in NSTs
2011 Ushida et al.
qMS-PCR Tissues (n = 161 TGCTs,n = 16 controls)
Differential methylation of
CRIPTO, HOXA9, MGMT,
RASSF1A and SCGB3A1 gene
promoters among TGCT subtypes
2018 Costa et al.
Genome-wide
DNA methylation
analysis
Tissues (n = 130 TGCTs, n = 128
benign neighboring testes)
DPPA3 is hypomethylated in both
SEs and NSTs; hypermethylation
of HM13 in NSTs and
subtype-specific
hypermethylation of H19 in TEs
2016 Killian et al.
Genome-wide
DNA methylation
analysis
Tissues (n = 91 GCTs) and GCT
cell lines
SEs, dysgerminomas and STs are
globally hypomethylated,
while ECs, NSTs and type I TEs
are hypermethylated
2015 Rijlaarsdam et al.
Genome-wide
DNA methylation
analysis; RT-qPCR
GCT cell lines
Localized hypermethylation
status in YSTs vs. disperse
hypermethylation status in ECs
and TEs
2015 Noor et al.
MeDIP; DNA-tiling
hybridization;
RT-qPCR; IHC
Tissues (n = 6 ECs)
Hypermethylated DMRs in ECs
(X- and Y-linked genes,
genes related to metabolism)
2016 Cheung et al.
Genome-wide
DNA methylation
analysis
Tissues (n = 137 TGCTs)
ECs display methylation at CpH
sites; methylation of BRCA1 and
RAD51C silencing in NSTs
2018 Shen et al.
MicroRNAs
miR library NA miR-372 and miR-373 netralizep53 (oncomiRs) 2006 Voorhoeve et al.
High-throughput
screening of 156
miRs; qPCR
GCT tissues (n = 69) and cell lines Relevance of miR-371–373 cluster;association with differentiation 2007 Gillis et al.
High-throughput
screening of 615
miRs; RT-qPCR
Pediatric malignant GCTs,
controls and GCT cell lines
(n = 48)
Overexpression of miR-371~373
and miR-372 clusters in all
tumor subtypes
2010 Palmer et al.
Multiplex PCR Serum (n = 1) of a four-year-oldboy
First report of utility of serum
miRs in GCTs (miR-371–373 and
miR-302 clusters); decrease
after treatment
2011 Murray et al.
RT-qPCR Serum (n = 12 patients,n = 11 controls)
Overexpression of miR-371-3 in
patients and decrease after
treatment
2012 Belge et al.
RT-qPCR Serum (n = 8 malignant GCTs) Additional specificity of usingmiR-367-3p 2012
Murray and
Coleman
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Table 4. Cont.
Methodology Sample Type Major Findings Year Author
Methylation
RT-qPCR Serum (n = 24 GCTs, n = 17controls) and GCT tissues (n = 15)
miR-371~373 measured in TVB in
6 patients (higher levels);
no correlation with levels
in tissues
2012 Dieckmann et al.
miR array;
RT-qPCR GCNIS tissue samples (n = 12)
Identification of miRs unique to
GCNIS cells 2012
Novotny and
Belling et al.
TSmiR Serum (n = 80 GCTs, n = 47controls, n = 12 non-GCT masses)
miR-371/372/373/367 panel with
98% sensitivity in diagnosis;
higher expression levels in
metastatic patients
2013 Gillis et al.
RT-qPCR
Serum (testing cohort: n = 30
patients and n = 18 controls;
validation cohort: n = 76 patients,
n = 84 controls)
miR-367-3p, miR-371a-3p,
miR372-3p and miR-373-3p
overexpressed in patients;
miR-371-a-3p showing 84.7%
sensitivity and 99% specificity
in diagnosis
2015 Syring et al.
RT-qPCR
Serum (n = 25 GCTs, 6 GCNIS,
n = 24 non-testicular malignancies,
n = 20 controls), seminal plasma
(n = 5), urine (n = 3) and pleural
effusions (n = 1)
miR-371a-3p detected in seminal
plasma and pleural effusions,
but not in urine; confirmation of
its value in serum
2015 Spiekermann et al.
High-throughput
screening of 750
miRs; RT-qPCR
Serum (n = 14 GCTs,
n = 11 controls)
Confirmation of the relevance of
miR-371–373 cluster; novel
relevant miRs identified
2015 Rijlaarsdam et al.
RT-qPCR Serum (n = 25 TGCTs, n = 4non-TGCTs, n = 17 controls)
Suggestion that normalization
(relative quantification) is not
required when
quantifying miR-371-3
2015 Spiekermann
RT-qPCR
Serum and cerebral spinal fluid
(n = 45 each) of 25
pediatric patients
Four serum microRNA panel
(miR-371a-3p, miR-372-3p,
miR-373-30 and miR-367-3p) with
high sensitivity and specificity in
discriminating intracranial GCT
vs. non-GCT malignancies;
first demonstration of
relapse detection
2016 Murray et al.
RT-qPCR GCT tissues and serum(n = 25 patients)
C19MC cluster overexpressed in
aggressive subtypes 2016 Flor et al.
RT-qPCR Tumor surrounding hydroceles(n = 9) and serum (n = 64 GCTs)
Hydroceles showing high levels of
miR-371a-3p; association with
tumor size; confirmed the value of
miR-371a-3p in follow-up
(relapse detection)
2016 Dieckmann et al.
ampTSmiR Serum (n = 250 TGCTs, n = 60non-TGCTs, n = 104 controls)
Largest series tested; panel
composed of miR-371a-3p,
miR-373-3p and miR-367-3p with
90% sensitivity and
91% specificity
2017 van Agthoven et al.
RT-qPCR Serum (n = 312 consecutivepatients with testicular disease)
Elevated levels aided in detection
of clinically silent GCTs
and metastases
2017 Anheuser et al.
RT-qPCR Serum and seminal plasma (n = 48patients, n = 28 controls)
miR-371a-3p suggested as a poor
biomarker in seminal plasma,
contrarily to miR-142
2017 Peloni et al.
RT-qPCR Serum (n = 166 GCTs,n = 106 controls)
miR-371a-3p shows the best
performance in TGCT detection
(88.7% sensitivity,
93.4% specificity)
2017 Dieckmann et al.
RT-qPCR Serum (n = 27 GCNIS) miR-371a-3p overexpressed inGCNIS patients 2017 Radtke et al.
ampTSmiR
Serum (n = 1 SE, n = 5 NST) of
patients with
relapse/residual disease
miR-371a-3p outperformed
classical protein markers in
detection of disease relapse,
except for mature TE
2017 van Agthoven et al.
RT-qPCR Tissues (n = 119 TGCTs,n = 15 controls)
miR-371a-3p discriminated TGCTs
from controls with 92% sensitivity
and 93% specificity; decreasing
expression with tumor
differentiation; TEs discriminated
from controls
2018 Vilela-Salgueiro et al.
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Table 4. Cont.
Methodology Sample Type Major Findings Year Author
Methylation
ampTSmiR Serum (n = 82 TGCTs)
miR-371a-3p discriminates viable
disease post-chemotherapy
(AUC = 0.87)
2018 Leão et al.
RT-qPCR Serum (24 TGCTs, clinical stage I) miR-371a-3p has a very shorthalf-life (<12 h) 2018 Radtke et al.
RT-qPCR Serum (n = 10 TGCT patients withrelapse)
Confirmed miR-371a-3p value in
detecting relapses 2018 Terbuch et al.
ampTSmiR Plasma (n = 199 TGCTs, beforechemotherapy)
miR-371a-3p predicts prognosis in
chemotherapy naïve patients 2018 Mego et al.
Teratoma assay
(mouse model) Plasma of mice
Value of miR-371 family members
in detecting undifferentiated and
potentially malignant elements
present in xenografts
2018 Salvatori et al.
miR-sequencing
data Tissues (n = 137 TGCTs)
miR-519 cluster overexpressed in
ECs; miR-375 overexpressed in
TEs and YSTs
2018 Shen et al.
Abbreviations: AR—androgen-receptor; AUC—area under the curve; COBRA—combined bisulfite
restriction analysis; DMR—differentially methylated region; EC—embryonal carcinoma; GCTs—germ cell
tumors; MeDIP—methylated DNA immunoprecipitation; miR—microRNA; NST—non-seminomatous tumor;
qMS-PCR—quantitative methylation-specific polymerase chain reaction; RT-qPCR—real-time quantitative
polymerase chain reaction; SE—seminoma; ST—spermatocytic tumor; TE—teratoma; TGCTs—testicular germ cell
tumors; TVB—testicular vein blood; YST—yolk sac tumor.
4. Conclusions
An overview of TGCTs from a developmental perspective was provided. This model underlies the
rationale for continuing to uncover epigenetic biomarkers that can be translated to the clinical practice.
This selection is powerful because of the consistency of the identified factors in crucial regulatory
pathways during embryogenesis, retained in TGCTs, and GCTs in general.
An integrated model (Figure 4) for defining TGCTs as distinct subtypes, concerning both genetic,
cytogenetic, and epigenetic biomarkers, is warranted. We have showed that both DNA methylation
profiles and miRs expression differ greatly among histological TGCT subtypes, and their detection in
liquid biopsies has proved its use, such as miR-371a-3p. Somatic mutations are scarce in TGCTs, and are
present mainly in SE components, especially those concerning KIT (which define a specific subset of
SEs). Extensive aneuploidy (and frequent presence of i(12p)) is a hallmark of TGCTs, regardless the
histologic type. Only by integrating all these factors can we reveal novel unappreciated diversity
within TGCTs as clinical entities.
Figure 4. Integrative view of the genvironmental model, with focus on genetic, cytogenetic,
and epigenetic factors, which are continuously modified and conditioned by the surrounding
environment, ultimately determining the cell fate and tumor progression (see text for details).
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The use of novel high-throughput techniques will surely continue to open the door for
characterizing new epigenetic aberrations in TGCTs, which can help us better understand their biology
and, ultimately, be used for diagnostic and follow-up purposes.
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Abbreviations
AFP alpha-fetoprotein
AR androgen receptor
β-HCG human chorionic gonadotropin, subunit β
CH choriocarcinoma
CNV copy number variation
COBRA combined bisulfite restriction analysis
DMR differentially methylated regions
DSD disorders of sex development
EC embryonal carcinoma
FTGCT familial TGCT
GCNIS germ cell neoplasia in situ
GCT germ cell tumor
GI genomic imprinting
GWAS genome wide association
hPSC human pluripotent stem cell
HR homologous recombination
LC lymphoid compensation
LDH lactate dehydrogenase
lncRNA long non-coding RNA
MeDIP methylated DNA immunoprecipitation
miR microRNA
ncRNA non-coding RNA
NST non-seminomatous tumor
PCR polymerase chain reaction
PGC primordial germ cells
RNA-seq RNA sequencing
SCNA somatic copy number aberrations
SE seminoma
sncRNA small non-coding RNA
SNP single nucleotide polymorphisms
snRNA small nuclear RNA
ST spermatocytic tumor
TDS testicular dysgenesis syndrome
TE teratoma
TGCT testicular germ cell tumor
TSmiR targeted serum miR
WES whole exome sequencing
WGS whole genome sequencing
XIC X-chromosome inactivation center
XIST X-inactive specific transcript
YST yolk sac tumor
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